此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

VOLta Medical AI-software in REal-World During AF Ablation (VOLTAIRE-AF)

2026年6月17日 更新者:Volta Medical

Real-World Experience of Volta Medical AI-software During AF Ablation Using Next-generation Mapping and Ablation Technologies

This PMCF study "VOLTAIRE-AF" will allow to observe acute and long-term safety and performance outcomes of the last generation of Volta Medical AI software (Volta AF-Xplorer II) during AF ablation using next-generation mapping and ablation technologies over a 24-month follow-up and in "real life"clinical practice, without any imposed clinical workflow.

研究概览

详细说明

All patients enrolled are treated for atrial fibrillation/tachycardia via a catheter ablation procedure using the last generation of Volta Medical AI software (Volta AF-Xplorer II) during the mapping phase to identify areas of interest specific to the patient. The ablation approach is free and chosen by the operator according to standard practice. Intraoperative and postoperative follow-up will be performed as in routine clinical practice during AF ablation procedures: hospitalization for ablation procedure and standard postoperative quarterly visits (at 3 months, at 6 months and/or 9 months as per the study investigator's Standard Of Care) then annual visits up to 24 months post-ablation. Adverse Events, recurrences of atrial arrhythmia, Heart Failure related symptom score ("NYHA") and AF related symptoms (EHRA score) are collected from the patient's enrollment until the patient's study termination. A quality-of-life questionnaire related to general health (EQ-5D-3L) is collected during the preoperative visit and at least during annual follow-up visits. The patient's study-termination corresponds to the last annual visit at 24 months post-ablation index.

研究类型

观察性的

注册 (估计的)

150

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Marseille、法国、13008
        • 招聘中
        • Hôpital Saint-Joseph Marseille
        • 接触:
          • Clément BARS, MD
      • Saint-Denis、法国、93207
        • 尚未招聘
        • Centre Cardiologique du Nord
        • 接触:
          • Antoine Lepillier, MD
      • Strasbourg、法国、67000
        • 尚未招聘
        • Clinique Rhéna
        • 接触:
          • Babé BAKOUBOULA, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

All adult patient candidate eligible for catheter ablation to treat paroxysmal or persistent atrial fibrillation, atrial tachycardia, de novo or after one or several previous ablation procedures, and for which the investigator considers using Volta AF-Xplorer II.

描述

Inclusion Criteria:

  1. Patient aged 18 years or older.
  2. Patient candidate for catheter ablation to treat paroxysmal or persistent atrial fibrillation, atrial tachycardia, de novo or after one or several previous ablation procedures, and for which the investigator considers using Volta AF-Xplorer II.
  3. Patient able and willing to provide written informed consent to participate in the study.
  4. Only for France: Patient affiliated to the French social security system.

Exclusion Criteria:

  1. Contraindication to AF/AT catheter ablation using RF and/or PFA.
  2. Patient who is or could potentially be pregnant.
  3. Person deprived of liberty or under guardianship.
  4. Person unable to undergo a medical monitoring for geographical, social or psychological reasons.
  5. Patient's refusal to participate in the study.
  6. Enrollment in a premarket clinical study evaluating device, drug or biologic product.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Freedom from clinically significant AF or atrial arrhythmia recurrence, after one or multiple ablation procedures, with or without antiarrhythmic drugs, at 12 and 24 months.
大体时间:24 months
An Atrial Arrhythmia episode (AF/AFL/AT ≥ 30s) will be determined to be clinically significant if it results in an unexpected treatment change (e.g. new anti-arrhythmic drug or higher dose of AAD, repeat ablation procedure, DC cardioversion), or if it is accompanied by worsening of symptoms related to AF, considering a standard 3-month blanking period.
24 months
Volta AF-Xplorer II-related Serious Incident rate
大体时间:24 months
24 months
Ablation procedure-related Serious Adverse Event rate
大体时间:24 months
24 months

次要结果测量

结果测量
大体时间
Progression of Quality-Of-Life score ("EQ-5D-3L") during the study (at inclusion, at quarterly visits, at 12 months and at 24 months).
大体时间:24 months
24 months
Progression of the AF related symptom score ("EHRA") during the study (at inclusion, at quarterly visits, at 12 months and at 24 months).
大体时间:24 months
24 months
Progression of the Heart Failure related symptom score ("NYHA") during the study (at inclusion, at quarterly visits, at 12 months and at 24 months).
大体时间:24 months
24 months
Hospitalization rate during the post-ablation follow-up period.
大体时间:24 months
24 months
Serious Adverse Event rate during the post-ablation follow-up period.
大体时间:24 months
24 months
Average number of ablation procedures per patient up to 24 months follow-up.
大体时间:24 months
24 months
Average number of cardioversions per patient up to 24 months follow-up
大体时间:24 months
24 months
Progression of patient proportion under antiarrhythmic drugs and/or anticoagulant treatments during the study.
大体时间:24 months
24 months
Health economics analysis including QALY metric
大体时间:24 months
24 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Clément BARS, MD、Hôpital Saint Joseph Marseille

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月16日

初级完成 (估计的)

2030年6月1日

研究完成 (估计的)

2030年6月1日

研究注册日期

首次提交

2026年5月27日

首先提交符合 QC 标准的

2026年5月27日

首次发布 (实际的)

2026年6月2日

研究记录更新

最后更新发布 (实际的)

2026年6月22日

上次提交的符合 QC 标准的更新

2026年6月17日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅